Allergan Wins Just $48.5K At Trial Over Imprimis False Ads
Law360 (May 16, 2019, 4:29 PM EDT) -- A California federal jury on Thursday ordered Imprimis Pharmaceuticals to pony up just $48,500 to competitor Allergan after finding the compound drug company cost Allergan business by using false advertisements to trick doctors into thinking its eye-treatment drugs used FDA-approved ingredients — far short of the millions Allergan sought.
A jury found that false advertising statements by Imprimis Pharmaceuticals harmed Allergan’s business, but declined to award damages for profits Imprimis made as a result of the deception. (AP)
After deliberating just over four hours Thursday, the jury found that false advertising statements made by Imprimis Pharmaceuticals Inc., including that its products...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!